Former Chief Scientific Officer and President of Research & Development, Pfizer
Search every verified Mikael Dolsten interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Mikael Dolsten, former Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer, has discussed his views on the relationship between science and society. He stated that science should be separate from politics and that scientists need to argue for science, particularly in the face of anti-vaccine movements and misinformation. Dolsten also commented on the transition from academia to industry, saying that in the past it was seen as a continuum with a shared purpose, unlike the more contentious relationship he perceives today. He has also spoken about the importance of effective science communication to the public and the need for scientists to work as teams to avoid becoming victims of politicization. Dolsten has reflected on his tenure at Pfizer, noting that during his 16-year career there, he secured 36 medicine and vaccine approvals and advanced over 150 drug candidates to clinical trials. He described the development of the COVID-19 vaccine, stating that Pfizer used company resources without taxpayer money and that the company made early decisions to start clinical trials and launch large-scale manufacturing. He also discussed the development of Paxlovid, which he said reduced hospitalization and death from COVID-19 by 90%. Dolsten currently serves on the boards of several companies, including Agilent Technologies and Rocket Pharmaceuticals, and on the private company boards for ImmuneAI, Fair Journey Biologics, Orbit Medicine, and Orgen Therapeutics.
“I see a lot of companies trying to arm the immune system, going beyond removing the brake with the PD1/PDL1 stuff that we were trying in those days.”
“So it's a fantastic renaissance and, again, being at the right time with a technology is critical.”
“You have to be very diligent in understanding when the technology should continue to evolve and when it shouldn't.”
“That decision—when to push a technology and when to focus—is often what's good for smaller biotech to focus on a technology.”
What if your research predicted the future? Pfizer's former CSO and Novo Nordisk board member, Mikael Dolsten, shares how his ...
Are you about to transition from academia to the biotech industry? Hear what Mikael Dolsten, former CSO of Pfizer and board ...
Nucleate Podcast was honored to host Dr. Dolsten, former CSO of Pfizer and board member of Novo Nordisk. During his career ...
Meet Mikael Dolsten, former Chief Scientific Officer at Pfizer and board member of Novo Nordisk. He led thousands of scientists ...
In this episode, we meet with Mikael Dolston, former Chief Scientific Officer of Pfizer and board member of Novo Nordisk. Born in ...
Mikael Dolsten, chief science officer and president, worldwide research development, Pfizer, Inc., expresses his gratitude for Dr.
Mikael Dolsten, Pfizers globala forskningschef, utnämndes till Årets svensk i världen 2021. I en exklusiv föreläsning berättar pristagaren bland annat om hur världens främsta forskare i kamp mot tiden lyckades ta fram ett vaccin mot covid-19.
Currently playing a critical role in delivering hope for a post-pandemic future, Pfizer is making cell and gene therapies important components in its drug development portfolio. This conversation will explore the development of the Pfizer/BioNTech COVID-19 vaccine and scientific opportunity for mRNA, Pfizer’s efforts in gene therapy for some rare diseases, the role of partnerships and collaborations in the Pfizer strategy, and how the company plans to address manufacturing and bioprocessing needs as CGT products emerge. Introducer: Jonathan Kraft, President, The Kraft Group; Chairman of the B…
Dr. Mikael Dolsten, Chief Scientific Officer & President, Worldwide Research, Development and Medical, Pfizer with The Hill's ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Mikael Dolsten.